Gregorius, Jonas http://orcid.org/0000-0002-6416-8289
Wang, Chen
Stambouli, Oumaima
Hussner, Tanja
Qi, Yachao
Tertel, Tobias
Börger, Verena
Mohamud Yusuf, Ayan
Hagemann, Nina
Yin, Dongpei
Dittrich, Robin
Mouloud, Yanis
Mairinger, Fabian D.
Magraoui, Fouzi El
Popa-Wagner, Aurel
Kleinschnitz, Christoph
Doeppner, Thorsten R.
Gunzer, Matthias
Meyer, Helmut E.
Giebel, Bernd
Hermann, Dirk M.
Funding for this research was provided by:
ERA-NET EuroTransBio (EV Trust, EV Trust)
Deutsche Forschungsgemeinschaft (HE3173/11-1, HE3173/12-1, HE3173/13-1)
National Authority for Science, Research and Innovation (UEFISCDI, PN-III-P4-ID-PCE-2016-0340, PN-III-P2-2.1-PED-2016-1013, PN-III-P4-ID-PCE-2016-0215, UEFISCDI, PN-III-P4-ID-PCE-2016-0340, PN-III-P2-2.1-PED-2016-1013, PN-III-P4-ID-PCE-2016-0215)
LeitmarktAgentur.NRW
European Regional Development Fund
Universitätsklinikum Essen
Article History
Received: 17 December 2020
Accepted: 18 May 2021
First Online: 8 June 2021
Change Date: 1 July 2021
Change Type: Update
Change Details: In this article the given and family name of Ayan Mohamud Yusuf was incorrectly structured.
Declarations
:
: B.G. and D.M.H. hold patents for the application of extracellular vesicles for the treatment of inflammatory conditions (EP2687219A1 pending; US9877989B2 issued). B.G. is a Scientific Board member of Evox Therapeutics and Innovex Therapeutics SL. Besides, the authors report no conflicts of interest.
: Performed with government approval (Northrhine-Westphalian State Agency for Nature, Environment and Consumer Protection, Recklinghausen; permission G1680/18).
: All authors read and consented the final version of this paper.